[1] | Bacchi, C. J., Goldberg, B., Carofalo-Hannan, J., Rattendi, D., Lyte, P. and Yarlett, N, “In vivo effects of α-DL-Difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei,” J. Biochem., 309. 737-40. 1995. |
|
[2] | Bitonti, A. J., Bacchi, C. J., McCann, P. P. and Sipertsma, A, “Intestinal changes caused by DL-α-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase,” Biochem. Pharmacol., 34. 1773-78. 1985. |
|
[3] | McCann, P. P., Bbacchi, C. J. and Clarkson, A. B, “In vivo effects of α-DL-Difluoromethyl ornithine on the metabolism and morphology of Trypanosoma brucei,” Med. Biol., 59. 434-37. 1981. |
|
[4] | Sjoerdsma, A, “Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-α-difluoromethylornithine), an inhibitor of ornithine decarboxylase,” Clin. Pharmacol. Ther., 30. 3-8. 1981. |
|
[5] | Sjoerdsma, A. and Schechter, P, “Difiuoromethylornithine in the treatment of African trypanosomiasis,” Clin. Pharmacol. Ther., 35. 287-90. 1984. |
|
[6] | Available: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&search Term=eflornithine&Search_Button=Submit. [April 18, 1986]. |
|
[7] | Pepin, J., Guern, C., Milord, F. and Schechter, P. J, “Difluoromethylornithine for arseno-resistant trypanosoma brucei gambiense sleeping sickness,” The Lancet, 330. 1431-1433. 1987. |
|
[8] | Merali, S. and Clarkson, A. B. Jr, “Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine,” Antimicrob. Agents Chemother., 40. 973-978. 1996. |
|
[9] | Balfour, J. A. and McClellan, K, “Topical eflornithine,” Am. J. Clin. Dermatol, 2(3). 197-201. |
|
[10] | Cohen, J. L., Ko, R. J., Lo, A. T., Shields, M. D. and Gilman, T. M, “High-pressure liquid chromatographic analysis of eflornithine in serum,” J. Pharm. Sci., 78(2). 114-6. Feb. 1989. |
|
[11] | Huebert, N. D., Schwartz, J. J. and Haegele, K. D, “ Analysis of 2-difluoromethyl-DL-ornithine in human plasma, cerebrospinal fluid and urine by cation-exchange high-performance liquid chromatography,” J. Chromatogr. A., 762(1-2). 293-8. Feb. 1997. |
|
[12] | Saravanan, C., Kumudhavalli, M. V., Kumar, M. and Jayakar, B, “ A new validated RP-HPLC method for estimation of eflornithine hydrochloride in tablet dosage form,” J. Phar. Res., 2. 1730-1731. 2009. |
|
[13] | Kilkenny, M. L., Slavik, M., Christopher, M. R. and Stobaugh, J. F, “Plasma analysis of alpha-difluoromethylornithine using pre-column derivatization with naphthalene-2,3-dicarboxaldehyde/CN and multidimensional chromatography,” J. Pharm. Biomed. Anal., 17. 1205-1213. 1998. |
|
[14] | Jansson-Löfmark, R., Römsing, S., Albers, E. and Ashton, M, “Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-l-cysteine and liquid chromatography with UV detection,” Biomed. Chromatogr., 24(7). 768-773. July 2010. |
|
[15] | Malm, M. and Bergqvist, Y, “Determination of eflornithine enantiomers in plasma, by solid-phase extraction and liquid chromatography with evaporative light-scattering detection,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 846. 98-104. 2007. |
|
[16] | Kumar, A., Venkatesh, Prasad, S. P., Mohan, S. and Kumar, P, “Spectrophotometric determination of eflornithine hydrochloride as active pharmaceutical ingredient using sodium 1,2-naphthoquinone-4-sulfonate as the derivative chromogenic reagent,” Trade Sci. Inc., 7, 2008. |
|
[17] | Kumar, A., Venkatesh, Prasad, S. P., Mohan, S. and Singh, A. K, “Estimation of eflornithine hydrochloride by UV spectroscopy,” Trade Sci. Inc., 8. 2009. |
|
[18] | Validation of Analytical Procedures, Methodology ICH Harmonised Tripartite Guideline, Having Reached Step 4 of the ICH Process at the ICH Steering Committee meeting on November 6, 1996. |
|